Skip to main content
Move the World.
FDA Approves First Mute Button for Genetic Diseases
Credit: Jeremy Keith

The FDA has just approved a breakthrough genetic treatment, a first of its kind therapy that silences a gene that causes amyloidosis and nerve damage. The treatment relies on RNAi, or "interfering" RNA, to block certain strands of DNA from being translated into proteins. Unlike traditional gene therapy, the technique doesn't remove or alter the underlying mutation, but it effectively "mutes" it so it can't do any damage.

Developed by Alnylam Pharmaceuticals, this is the first time that the technique has been approved to treat disease in humans, but scientists have used it for years to "knock down" genes in mice in order to model various diseases. The potential upside for therapies with RNAi is huge, which is why its discoverers won the Nobel Prize for Medicine in 2006. This is likely to be the first of many advanced treatments to deploy the technique. It also has widespread potential applications in agriculture, from suppressing natural toxins and allergens in crops to targeting pests and weeds.

How to Build Stuff (Or Not)

To wildly oversimplify things, your body is made of cells, and cells are made of proteins. To make proteins, cells use a molecule called RNA to carry instructions from your DNA to protein factories called ribosomes. RNA translates DNA from abstract code into specific instructions for assembling proteins.

Many types of genetic disease (whether inherited or developed later in life) are caused by cells making the wrong kind of protein—maybe it's misshapen, or toxic, or in the wrong organ, or there's simply too much of it. Traditional pharmaceuticals use chemical compounds to block the protein from doing its job, break it down, or suppress it from being made. But hitting the right target in complex chemical reactions is extremely challenging, and it can take literally decades of trial and error to find the right chemical.

Gene therapies try to go right for the source, by deleting or replacing the mutated DNA that has the bad protein instructions. But your cells really don't like anything messing with your DNA (for very good reason), so it's turned out to be difficult to edit enough cells (potentially billions of them) to make a dent in many diseases.

A Third Way

When pharmaceuticals and biotech fail, there's another approach, right in the middle: cut off RNA messengers before they can turn DNA into proteins. Fortunately, your body already has a process for doing this, called RNA interference (RNAi). Why would cells want to interfere with their own RNA? Often, it's just another way to control the rate of protein production, but it can also be a defense mechanism against viruses that try to sneak their RNA into the cell to hijack its protein machinery.

RNAi is a highly complex process, but fundamentally, it's a way to shred RNA before it can be translated into protein. Researchers have used the technique successfully to silence gene expression in mice to simulate diseases and then test treatments, and there's a number of applications in the works for modifying crops to remove natural allergens or toxins. In 2006, the discoverers of RNAi won the Nobel Prize in Medicine, and the 12 years since have been a race to develop and commercialize a new class of drugs based on their breakthrough.

The Drug

Alnylam won that race this month, and their therapy will be the first to use RNAi to treat disease in humans. The FDA approved only a very narrow use of the drug, treating neuropathy or nerve pain caused by a rare hereditary form of amyloidosis. But some experts believe that it could eventually be approved for treating heart damage, another serious effect of amyloidosis, and even the non-hereditary forms of the disease, which are still ultimately caused by the overproduction of amyloid protein.

The company has three other RNAi drugs in the pipeline, likely headed for approval soon, intended to treat causes of high cholesterol, porphyria, and hemophilia. FDA Commissioner Scott Gottlieb made optimistic comments about the future of RNAi therapies in his press release announcing the drug's approval: "This approval is part of a broader wave of advances that allow us to treat disease by actually targeting the root cause, enabling us to arrest or reverse a condition, rather than only being able to slow its progression or treat its symptoms."

"New technologies like RNA inhibitors,that alter the genetic drivers of adisease, have the potential to transformmedicine."

Scott GottliebFDA Commissioner

This drug, the crest of that wave of innovation, will come at a steep price—nearly $350,000, even after discounts. At that price, Alnylam hopes to rapidly recoup its estimated $2.5 billion investment in research and development, but insurance companies and governments will likely balk at the cost. It remains to be seen if these treatments can become either widespread or cost effective with mid-six-figure sticker prices.

Up Next

Dope Science
The Case for Love-Enhancing Drugs
interview with Brian D. Earp
Dope Science
The Case for Love-Enhancing Drugs
Drugs don’t just affect the user; they shape relationships too. And a pair of bioethicists thinks we should consider them for relationship enhancement.

Drugs don’t just affect the user; they shape relationships too. And a pair of bioethicists thinks we should consider them for relationship enhancement.

Future of Travel
Coast-To-Coast in 30 Minutes: Solving the Physics of Hypersonic Flight
hypersonic flight
Future of Travel
Coast-To-Coast in 30 Minutes: Solving the Physics of Hypersonic Flight
Researchers are solving big design challenges of hypersonic flight with a surprisingly small wind tunnel, and it could revolutionize commercial air travel.

Researchers are solving big design challenges of hypersonic flight with a surprisingly small wind tunnel, and it could revolutionize commercial air travel.

Criminal Justice
Algorithm Clears Thousands of Marijuana Convictions in Just One Minute
criminal record clearance
Criminal Justice
Algorithm Clears Thousands of Marijuana Convictions in Just One Minute
With this new system that identifies candidates for criminal record clearance and even auto-fills forms, offenders don’t even need to apply.

With this new system that identifies candidates for criminal record clearance and even auto-fills forms, offenders don’t even need to apply.

Below the Surface
The Fleet of Underwater Drones Probing Earth’s Interior
underwater drones
Below the Surface
The Fleet of Underwater Drones Probing Earth’s Interior
The Earth’s interior may be the last wild frontier, but not for long. These underwater drones are scanning the ocean to create a 3D model of its internal dynamics.

The Earth’s interior may be the last wild frontier, but not for long. These underwater drones are scanning the ocean to create a 3D model of its internal dynamics.

Future of Medicine
Using Artificial Intelligence to Improve Breast Cancer Screening
Scientists Are Using AI to Improve Breast Cancer Screening
Future of Medicine
Using Artificial Intelligence to Improve Breast Cancer Screening
Computer scientists at MIT created a new algorithm for breast cancer screening to predict whether a patient will develop the disease in the next 5 years.

Computer scientists at MIT created a new algorithm for breast cancer screening to predict whether a patient will develop the disease in the next 5 years.

Dispatches
A Hidden Benefit of Banned Antimicrobial Soap: Treating Cystic Fibrosis Infections
A Hidden Benefit of Banned Antimicrobial Soap: Treating Cystic Fibrosis Infections
Dispatches
A Hidden Benefit of Banned Antimicrobial Soap: Treating Cystic Fibrosis Infections
The FDA banned triclosan from hand soap, but new research shows that it can supercharge old antibiotics.
By Chris Waters

The FDA banned triclosan from hand soap, but new research shows that it can supercharge old antibiotics.

Dispatches
The Cost of Sucking Carbon Out of the Air Just Fell By 85%
The Cost of Sucking Carbon Out of the Air Just Fell By 85%
Dispatches
The Cost of Sucking Carbon Out of the Air Just Fell By 85%
It's not there yet, but carbon capture just got interesting.

It's not there yet, but carbon capture just got interesting.

Coded
Coded Trailer
Coded Trailer
Watch Now
Coded
Coded Trailer
Meet the programmers on the frontlines of the war over security and privacy.
Watch Now

There’s an invisible war being waged. Foreign governments are hacking major corporations. Major corporations are collecting massive amounts of consumer data. And the NSA is listening to everything. But a new generation of programmers armed with powerful technology is rising up and fighting back.

Self-Driving Cars are Finally Here. Sort Of.
Self-Driving Cars are Finally Here. Sort Of.
Self-Driving Cars are Finally Here. Sort Of.
Uber rolled out self-driving cars in Pittsburgh, but they're not totally autonomous. Yet. Under Pennsylvania law,...
By Mike Riggs

Uber rolled out self-driving cars in Pittsburgh, but they're not totally autonomous. Yet. Under Pennsylvania law, every car still needs an operator.